IDYA 8-K
IDEAYA Biosciences, Inc. (IDYA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
|
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IDEAYA BIOSCIENCES, INC. |
|
|
|
Date: August 5, 2025 |
By: |
/s/ Yujiro Hata |
|
|
Yujiro Hata |
|
|
President and Chief Executive Officer |
Exhibit 99.1
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., August 5, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology company committed to advancing the discovery, development, and commercialization of transformative precision medicines to address unmet medical needs in cancer, provided a business update and announced financial results for the second quarter ended June 30, 2025.
"We look forward to a catalyst rich period with six clinical data updates guided from now to year-end across three clinical stage programs, including two oral presentations that have been accepted at major medical conferences and our targeted top-line randomized median PFS results for the darovasertib and crizotinib combination in 1L HLA-A2 negative MUM to potentially enable our first accelerated approval filing in the U.S. We are also excited to host
Exhibit 99.1
our 10-year Anniversary R&D Day in New York City on September 8th, where we will present multiple data updates across our potential first-in-class clinical pipeline and highlight our strategic vision and pioneering research in cancer biology and drug discovery," said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences.
Selected Pipeline Developments and Upcoming Milestones
Darovasertib
Exhibit 99.1
IDE397 (MAT2A)
IDE849 (DLL3 TOP1i ADC)
Other programs
Exhibit 99.1
R&D Day - September 8, 2025
Other corporate updates
Financial Results for the Quarter Ended June 30, 2025
Exhibit 99.1
As of June 30, 2025, IDEAYA had cash, cash equivalents and marketable securities of approximately $991.9 million, compared to $1.05 billion as of March 31, 2025. The decrease was primarily driven by net cash used in operations.
Research and development (R&D) expenses for the three months ended June 30, 2025 totaled $74.2 million compared to $70.9 million for the three months ended March 31, 2025. The increase was primarily due to higher clinical trial expenses to support our clinical pipeline and personnel-related expenses.
General and administrative (G&A) expenses for the three months ended June 30, 2025 totaled $14.6 million compared to $13.5 million for the three months ended March 31, 2025. The increase was primarily due to higher personnel-related expenses to support our growth.
The net loss for the three months ended June 30, 2025, was $77.5 million compared to the net loss of $72.2 million for the three months ended March 31, 2025. Total stock compensation expense for the three months ended June 30, 2025, was $11.9 million compared to $10.2 million for the same period in 2024.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website, at its Investor Relations page: https://ir.ideayabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to (i) the timing and content of clinical program updates, regulatory updates, clinical trial data readouts, including those at medical conferences and IDEAYA’s R&D Day; (ii) the potential therapeutic benefits of IDEAYA therapeutics; (iii) the translation of preliminary clinical trial results into future clinical trial results and/or regulatory approval; (iv) timing of development and regulatory milestones; (v) the timing of new IND applications; and (vi) the extent to which IDEAYA's existing cash, cash equivalents, and marketable securities will fund its planned operations. Such forward-looking statements involve substantial risks and
Exhibit 99.1
uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
[email protected]
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
June 30, 2025 |
|
|
March 31, 2025 |
|
|
June 30, 2025 |
|
|
June 30, 2024 |
|
||||
|
|
(Unaudited) |
|
|
(Unaudited) |
|
||||||||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
74,226 |
|
|
$ |
70,886 |
|
|
$ |
145,112 |
|
|
$ |
97,338 |
|
General and administrative |
|
|
14,580 |
|
|
|
13,503 |
|
|
|
28,083 |
|
|
|
18,606 |
|
Total operating expenses |
|
|
88,806 |
|
|
|
84,389 |
|
|
|
173,195 |
|
|
|
115,944 |
|
Loss from operations |
|
|
(88,806 |
) |
|
|
(84,389 |
) |
|
|
(173,195 |
) |
|
|
(115,944 |
) |
Interest income and other income, net |
|
|
11,315 |
|
|
|
12,211 |
|
|
|
23,526 |
|
|
|
23,600 |
|
Net loss |
|
|
(77,491 |
) |
|
|
(72,178 |
) |
|
|
(149,669 |
) |
|
|
(92,344 |
) |
Unrealized (losses) gains on marketable securities |
|
|
(64 |
) |
|
|
773 |
|
|
|
709 |
|
|
|
(1,978 |
) |
Comprehensive loss |
|
$ |
(77,555 |
) |
|
$ |
(71,405 |
) |
|
$ |
(148,960 |
) |
|
$ |
(94,322 |
) |
Net loss per share |
|
$ |
(0.88 |
) |
|
$ |
(0.82 |
) |
|
$ |
(1.69 |
) |
|
$ |
(1.21 |
) |
Weighted-average number of shares |
|
|
88,472,197 |
|
|
|
88,356,335 |
|
|
|
88,414,586 |
|
|
|
76,535,607 |
|
Exhibit 99.1
IDEAYA Biosciences, Inc.
Condensed Balance Sheet Data
(in thousands)
|
|
June 30, |
|
|
December 31, |
|
||
|
|
2025 |
|
|
2024 |
|
||
|
|
(Unaudited) |
|
|||||
Cash and cash equivalents and short-term and |
|
$ |
991,869 |
|
|
$ |
1,082,151 |
|
Total assets |
|
|
1,041,270 |
|
|
|
1,124,091 |
|
Total liabilities |
|
|
81,617 |
|
|
|
64,944 |
|
Total liabilities and stockholders' equity |
|
$ |
1,041,270 |
|
|
$ |
1,124,091 |
|